Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Post Marketing Surveillance Study of the Labeled Use of Remicade (Infliximab) in Patients With Chronic Inflammatory Diseases

Next Previous
Trial Profile

Post Marketing Surveillance Study of the Labeled Use of Remicade (Infliximab) in Patients With Chronic Inflammatory Diseases

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 10 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Infliximab (Primary)
  • Indications Ankylosing spondylitis; Crohn's disease; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Adverse reactions
  • Acronyms REMission
  • Sponsors Merck & Co; Merck Sharp & Dohme Corp.; Schering-Plough

Most Recent Events

  • 11 Sep 2012 Drug company changed from Schering Plough to Merck & Co as reported by ClinicalTrials.gov.
  • 17 Oct 2011 Actual patient no is 3000 as reported by ClinicalTrials.gov.
  • 13 Oct 2011 Actual end date (August 2011) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top